|
|
Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >
Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis : Post-Marketing Surveillance of 251 Patients
| Title: | Long-Term Safety and Effectiveness of Adalimumab in Japanese Patients with Noninfectious Intermediate, Posterior, or Panuveitis : Post-Marketing Surveillance of 251 Patients |
| Authors: | Kenichi, Namba Browse this author →KAKEN DB | | Toshikatsu, Kaburaki Browse this author | | Hidekazu, Tsuruga Browse this author | | Ogawa, Yohei Browse this author | | Iwashita, Eri Browse this author | | Goto, Hiroshi Browse this author |
| Keywords: | Adalimumab | | Behcet's Disease | | Sarcoidosis | | Uveitis | | Vogt-Koyanagi-Harada Disease |
| Issue Date: | 1-Jun-2022 |
| Publisher: | Springer |
| Journal Title: | Ophthalmology and Therapy |
| Volume: | 11 |
| Issue: | 3 |
| Start Page: | 1147 |
| End Page: | 1161 |
| Publisher DOI: | 10.1007/s40123-022-00493-z |
| Abstract: | Introduction The aim of this nationwide, prospective post-marketing surveillance was to assess the safety and effectiveness of up to 52 weeks of adalimumab treatment in patients with noninfectious intermediate, posterior, or panuveitis in Japanese clinical practice. Methods This post-marketing surveillance was conducted at 60 medical facilities in Japan from October 2016 to June 2020. Patients with noninfectious intermediate, posterior, or panuveitis who were administered adalimumab (Humira(R), AbbVie Inc.) for the first time were eligible. Subcutaneous adalimumab was initially administered at 80 mg, followed by 40 mg 1 week later, then 40 mg every 2 weeks. Safety measures included the incidence of adverse events (AEs) and adverse drug reactions (ADRs; primary endpoint). Effectiveness measures included visual acuity, anterior chamber cell grade, vitreous haze, macular edema, foveal retinal thickness, uveitis recurrence rate, and oral corticosteroid dose. Health-related quality of life was evaluated using the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25). Results During 52 weeks of surveillance, AEs and ADRs occurred in 70 (27.9%) and 47 (18.7%) of 251 patients, respectively. The most common ADR was infection (21/251 patients; 8.4%), including serious infections in eight (3.2%) patients. ADRs were more frequent in patients >= 65 years of age, those with concurrent diseases, and those with past medical history. Four patients developed tuberculosis. The uveitis recurrence rate was 24.8% (61/246 patients). All effectiveness measures tended to improve from baseline to week 52, and mean corticosteroid doses decreased. Clinically meaningful changes were observed for most VFQ-25 subscales. Conclusions The safety profile of adalimumab was generally consistent with previous reports, and no new safety concerns were identified. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/85586 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
